Evercore ISI Lowers Moderna (NASDAQ:MRNA) Price Target to $50.00

Moderna (NASDAQ:MRNA) had its target price reduced by equities researchers at Evercore ISI from $60.00 to $50.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “in-line” rating on the stock. Evercore ISI’s target price would suggest a potential upside of 11.26% from the company’s current price.

Several other equities research analysts also recently commented on MRNA. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 price objective (down from $115.00) on shares of Moderna in a report on Monday, November 18th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. UBS Group reduced their price target on Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, Berenberg Bank increased their price objective on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $69.79.

Moderna Trading Up 7.9 %

NASDAQ:MRNA opened at $44.94 on Monday. Moderna has a 12 month low of $31.94 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $40.79 and its 200 day moving average is $62.18. The stock has a market capitalization of $17.29 billion, a PE ratio of -7.72 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.39) earnings per share. Sell-side analysts expect that Moderna will post -9.27 earnings per share for the current year.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last 90 days. 15.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Axiom Advisory LLC grew its holdings in shares of Moderna by 1.6% during the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after purchasing an additional 198 shares during the last quarter. Arkadios Wealth Advisors boosted its position in Moderna by 2.2% during the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock valued at $764,000 after buying an additional 243 shares during the period. Knuff & Co LLC boosted its position in Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after buying an additional 244 shares during the period. Stephens Inc. AR grew its stake in shares of Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after buying an additional 245 shares during the last quarter. Finally, Mather Group LLC. increased its holdings in shares of Moderna by 25.7% in the third quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock worth $86,000 after buying an additional 262 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.